IMI
Asset Logo

Infinity Mining Limited

๐Ÿ‡ฆ๐Ÿ‡บ ASX

โ›๏ธ MINING

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

-32.02%
Annual Growth

3 years average annual growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

2
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

Infinity Mining Ltd. engages in the exploration and development of gold, copper, base metals and lithium mineral properties. These tenements are located in highly prospective Lithium, Nickel, Copper and Gold terranes. The firm's is focused on substantial East Pilbara lithium assets. The Pilbara project tenements comprise an extensive portfolio of Lithium, Gold, Nickel, Copper and Zinc exploration tenements located in the Pilbara region of northwest Western Australia, including the Tambourah South, Tambourah North, Strelley Gorge, Hillside and Panorama Projects. The Tambourah South Project is located 80 kilometers (km) southwest of Marble Bar and 155 km south of Port Headland. The Panorama Project encompasses three tenements and is prospective for a range of target types. The Central Goldfields region is host to deposits of gold, base metals and nickel hosted within greenstone belts and granite intrusives.

๐Ÿ“ˆ Performance

Price History

-93.50%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.01

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in IMI

2

๐Ÿ“Š Total Capital Earnings

$12.32

๐Ÿ”ƒ Average investment frequency

17 weeks

๐Ÿ’ต Average investment amount

$1,047

โฐ Last time a customer invested in IMI

322 days
IMI investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

33%

Less than 50k

67%
๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

50%

35 - 90

50%
๐Ÿ™‹ Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in IMI also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

4.43%

๐Ÿ“Š Share price

$104.33 AUD

๐Ÿงฑ MATERIALS

โ›ณ๏ธ DIVERSIFIED

๐Ÿ’ธ FINANCIALS

Find Out More

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

4.09%

๐Ÿ“Š Share price

$68.57 AUD

๐ŸŒ GLOBAL

โ›ณ๏ธ DIVERSIFIED

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

๐Ÿ™Œ Performance (5Yr p.a)

13.26%

๐Ÿ“Š Share price

$15.78 AUD

๐Ÿ“ˆ HIGH PRICE GROWTH

๐Ÿค– TECHNOLOGY

๐ŸŒ GLOBAL

โ›ณ๏ธ DIVERSIFIED

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

๐Ÿ™Œ Performance (5Yr p.a)

12.72%

๐Ÿ“Š Share price

$82.30 AUD

๐ŸŒ GLOBAL

๐Ÿ›๏ธ CONSUMER

๐Ÿญ INDUSTRIALS

๐Ÿค– TECHNOLOGY

๐Ÿ“ˆ HIGH PRICE GROWTH

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

13.28%

๐Ÿ“Š Share price

$134.96 AUD

๐ŸŒ GLOBAL

โ›ณ๏ธ DIVERSIFIED

๐Ÿค– TECHNOLOGY

๐Ÿ“ˆ HIGH PRICE GROWTH

Want more shares? Try these...

IMLC.AX was created on 2023-08-01 by IML. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the S&P/ASX 300 Accumulation Index (after fees and expenses and before taxes) on a rolling four-year basis.

๐Ÿ“Š Share price

$4.07 AUD

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3โ€™s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

๐Ÿ™Œ Performance (5Yr p.a)

3.46%

๐Ÿ“Š Share price

$0.30 AUD

๐Ÿงฌ BIOTECHNOLOGY

๐Ÿ•Š๏ธ SOCIALLY AWARE

Imdex Ltd. engages in the provision of mining equipment, technology, and services. The company is headquartered in Balcatta, Western Australia and currently employs 851 full-time employees. The Companyโ€™s product offering includes an integrated range of drilling optimization products, cloud connected rock knowledge sensors and data and analytics. Its geographical segments include Americas, Asia Pacific, and Africa/Europe. The Companyโ€™s solutions include software, mining technology, drilling optimization, downhole navigation, structural geology, in-field geo-analysis, and driller operable geophysics. Its brands include AMC and REFLEX technologies. Its products include IMDEXHUB-IQ, IMDEX MOBILE, AMC BORE HOLE STABILISER, IMDEX MUD AID, AMC BOS, and AMC SRU Range. Its drilling fluid range include cement & grouting additives, clay & shale stabilizers, drilling fluids equipment, filtrate control agents, flocculants & dispersants, foaming agents & detergents, lost circulation materials, lubricants & cutting oils, specialty products & chemicals, treating chemicals, viscosifiers, and weighting materials.

๐Ÿ™Œ Performance (5Yr p.a)

14.35%

๐Ÿ“Š Share price

$2.57 AUD

๐Ÿ•Š๏ธ SOCIALLY AWARE

๐Ÿ“ˆ HIGH PRICE GROWTH

โ›๏ธ MINING

ImExHS Ltd. engages in the development and sale of its Hiruko software platform. The company is headquartered in Mascot, New South Wales and currently employs 400 full-time employees. The company went IPO on 2005-12-14. The firm develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The firm's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.

๐Ÿ™Œ Performance (5Yr p.a)

185.13%

๐Ÿ“Š Share price

$0.40 AUD

๐Ÿฉบ HEALTH CARE

Compare
Add to watchlist